跳至主要内容
临床试验/EUCTR2006-001721-26-LT
EUCTR2006-001721-26-LT进行中(未招募)不适用

The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) - GeNeSIS

AB Eli Lilly Lietuva”0 个研究点目标入组 13,000 人开始时间: 2006年5月25日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
13,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Core programme: all patients treated with Humatrope for growth promotion
  • DNA analysis sub-study: patients who fulfil the scoring criteria
  • Growth prediction sub-study: therapy-naïve patients
  • SHOX deficiency sub-study: patients with Turner syndrome, Léri-Weill or Langer syndrome (with or without SHOX defect), or other growth disorder with proven SHOX defect, treated or non-treated (control group)
  • Neoplasia sub-study: patients with a history of neoplasia and endocrine or growth disorder, treated or non-treated (control group)
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients treated long-term data on efficacy of GH treatment
  • with other HGH

研究者

发起方
AB Eli Lilly Lietuva”

相似试验